[go: up one dir, main page]

PE20090884A1 - Compuestos de indol como activadores de glucoquinasa - Google Patents

Compuestos de indol como activadores de glucoquinasa

Info

Publication number
PE20090884A1
PE20090884A1 PE2008000659A PE2008000659A PE20090884A1 PE 20090884 A1 PE20090884 A1 PE 20090884A1 PE 2008000659 A PE2008000659 A PE 2008000659A PE 2008000659 A PE2008000659 A PE 2008000659A PE 20090884 A1 PE20090884 A1 PE 20090884A1
Authority
PE
Peru
Prior art keywords
indol
alkyl
methyl
glucokinase activators
compounds
Prior art date
Application number
PE2008000659A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Osamu Ujikawa
Masahiro Itoh
Kazuko Aoki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39010108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090884(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20090884A1 publication Critical patent/PE20090884A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE INDOL DE FORMULA (I), DONDE R1 ES H O HALOGENO; R2 ES UN GRUPO (a) O (b); A ES CH O N; R4 Y R5 SON ALQUILO C1-C6, CICLOALQUILO C3-C10 O JUNTOS FORMAN UN ANILLO HETEROCICLICO; R6, R7, R21 Y R22 SON H, CN, ACILO, ENTRE OTROS; W ES O O NR8; R8 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C10, ENTRE OTROS; R3 ES UN GRUPO HETEROCICLICO, ARILO C6-C14, ENTRE OTROS; R9, R10 Y R11 SON H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N,N-DIMETIL-2-{4-[(2-{7-[METIL(2-TIENILSULFONIL)AMINO]-1H-INDOL-2-IL}-1,3-TIAZOL-5-IL)METIL]PIPERAZIN-1-IL}ACETAMIDA, N-METIL-N-[2-(8-OXA-1-TIA-3-AZAESPIRO[4,5]DEC-2-EN-2-IL)-1H-INDOL-7-IL]TIOFEN-2-SULFONAMIDA, N-[2-[4-(HIDROXIMETIL)-4,5-DIHIDRO-1,3-TIAZOL-2-IL]-5-(2-METOXIETOXI)-1H-INDOL-7-IL]-N-METILPIRIDIN-2-SULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ACTIVADORES DE LA GLUCOQUINASA Y SON UTILES EN EL TRATAMIENTO DE LA DIABETES, COMPLICACIONES DIABETICAS Y OBESIDAD
PE2008000659A 2006-10-19 2008-04-16 Compuestos de indol como activadores de glucoquinasa PE20090884A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006285551 2006-10-19
PCT/JP2007/070772 WO2008050821A1 (en) 2006-10-19 2007-10-18 Indole compound

Publications (1)

Publication Number Publication Date
PE20090884A1 true PE20090884A1 (es) 2009-08-05

Family

ID=39010108

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000659A PE20090884A1 (es) 2006-10-19 2008-04-16 Compuestos de indol como activadores de glucoquinasa

Country Status (26)

Country Link
US (4) US8410087B2 (es)
EP (2) EP2074119A1 (es)
JP (1) JP5260507B2 (es)
KR (1) KR101444486B1 (es)
CN (1) CN101573357B (es)
AU (1) AU2007310064B2 (es)
BR (1) BRPI0717722A2 (es)
CA (1) CA2666973C (es)
CL (1) CL2008001017A1 (es)
CR (1) CR10748A (es)
EC (1) ECSP099330A (es)
GE (1) GEP20115241B (es)
IL (1) IL198154A (es)
MA (1) MA30890B1 (es)
ME (1) MEP11809A (es)
MX (1) MX2009003972A (es)
MY (1) MY158052A (es)
NO (1) NO20091948L (es)
NZ (1) NZ576570A (es)
PE (1) PE20090884A1 (es)
RU (1) RU2454415C9 (es)
TN (1) TN2009000129A1 (es)
TW (1) TWI460176B (es)
UA (1) UA97257C2 (es)
WO (1) WO2008050821A1 (es)
ZA (1) ZA200902585B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131000A2 (en) * 2007-04-16 2008-10-30 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
EP2149550A4 (en) 2007-04-27 2010-08-11 Takeda Pharmaceutical NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101784543B (zh) 2007-08-17 2013-10-16 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚和吲唑化合物
WO2009082152A2 (en) 2007-12-20 2009-07-02 Lg Life Sciences Ltd. Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
EP2230238B1 (en) * 2008-01-04 2013-12-11 LG Life Sciences Ltd. Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
RS53378B (en) 2008-04-10 2014-10-31 Takeda Pharmaceutical Company Limited CONDENSED RING UNITS AND THEIR USE
US8349886B2 (en) * 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP5597200B2 (ja) * 2008-08-18 2014-10-01 プロメガ コーポレイション ルミネッセンスを生じる化合物およびチトクロムｐ４５０３ａ酵素を検出するための方法
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
US8501804B2 (en) 2008-10-27 2013-08-06 Takeda Pharmaceutical Company Limited Bicyclic compound
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
US20120022078A1 (en) * 2009-04-09 2012-01-26 Msd K.K. Aryl indole derivatives
JP5657578B2 (ja) 2009-06-09 2015-01-21 武田薬品工業株式会社 新規な縮合環化合物およびその用途
MX2012001284A (es) 2009-07-28 2012-03-26 Takeda Pharmaceutical Tableta.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011136385A1 (en) 2010-04-27 2011-11-03 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.
PH12012502468A1 (en) 2010-06-16 2015-05-08 Takeda Pharmaceuticals Co Crystal of amide compound
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012036293A1 (ja) 2010-09-17 2012-03-22 武田薬品工業株式会社 糖尿病治療剤
UY33756A (es) 2010-11-30 2012-06-29 Takeda Pharmaceutical Compuesto biciclico
SG192645A1 (en) 2011-02-17 2013-09-30 Takeda Pharmaceutical Production method of optically active dihydrobenzofuran derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8921576B2 (en) * 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same
JPWO2013061962A1 (ja) 2011-10-24 2015-04-02 武田薬品工業株式会社 二環性化合物
JP6129850B2 (ja) 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
EP2816032A4 (en) 2012-02-13 2015-09-30 Takeda Pharmaceutical AROMATIC RING CONNECTION
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
EP2838891B1 (en) 2012-02-24 2017-08-02 Takeda Pharmaceutical Company Limited Aromatic ring compound as ghrelin o-acyltransferase inhibitor
WO2013147026A1 (ja) 2012-03-29 2013-10-03 武田薬品工業株式会社 芳香環化合物
WO2013155223A1 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
JPWO2013168759A1 (ja) 2012-05-10 2016-01-07 武田薬品工業株式会社 芳香環化合物
US9505772B2 (en) 2012-05-10 2016-11-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013183784A1 (en) 2012-06-05 2013-12-12 Takeda Pharmaceutical Company Limited Solid preparation
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
US9719970B2 (en) 2012-11-30 2017-08-01 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin D metabolites
JP6247697B2 (ja) 2013-03-14 2017-12-13 武田薬品工業株式会社 スピロアゼチジンイソキサゾール誘導体及びそのｓｓｔｒ５アンタゴニストとしての使用
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
TW201536767A (zh) 2013-07-09 2015-10-01 Takeda Pharmaceutical 雜環化合物
LT3031799T (lt) 2013-08-09 2018-06-25 Takeda Pharmaceutical Company Limited Aromatinis junginys
ES2835851T3 (es) * 2013-08-22 2021-06-23 Lg Chemical Ltd Compuesto de indol amida como inhibidor de necrosis
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
EP3604267A4 (en) 2017-03-31 2020-12-16 Takeda Pharmaceutical Company Limited Aromatic compound
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
JP7526716B2 (ja) 2018-03-23 2024-08-01 カーモット セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体の調節剤
WO2020045326A1 (ja) 2018-08-27 2020-03-05 株式会社スコヒアファーマ 安息香酸エステル化合物
JP2022503793A (ja) 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
CN109250963B (zh) * 2018-09-29 2021-07-16 福建省昊立建设工程有限公司 一种复合增韧混凝土及其制备方法
ES2986788T3 (es) 2020-02-07 2024-11-12 Gasherbrum Bio Inc Agonistas heterocíclicos de GLP-1
JP2023524603A (ja) 2020-03-25 2023-06-12 武田薬品工業株式会社 Ｇｉｆ受容体アゴニストペプチド化合物及びその使用
CN115335395A (zh) 2020-03-25 2022-11-11 武田药品工业株式会社 Gip受体激动剂肽化合物的qd给药及其用途
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
BR112023023559A2 (pt) 2021-05-13 2024-02-06 Carmot Therapeutics Inc Moduladores de receptores acoplados à proteína g
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
TW202435857A (zh) 2022-12-15 2024-09-16 美商迦舒布魯姆生物有限公司 具有glp-1促效劑活性之化合物之鹽及固體形式
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025015268A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulators of calcitonin receptor and/or amylin receptor activity
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656610B1 (fr) 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
ES2206469T3 (es) * 1993-09-10 2004-05-16 Eisai Co., Ltd. Derivados heterociclicos biciclicos de sulfonamida y ester sulfonico.
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
NZ506329A (en) * 1998-02-25 2004-01-30 Inst Genetics Llc Inhibitors of phospholipase enzymes
JP4007743B2 (ja) 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
DE60142961D1 (de) 2000-04-28 2010-10-14 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
EP2308839B1 (en) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
WO2007037534A1 (ja) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. ２－へテロアリール置換インドール誘導体
PA8793301A1 (es) 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados
NZ583267A (en) 2007-08-14 2012-03-30 Bayer Schering Pharma Ag Fused bicyclic pyrimidines
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
US8440701B2 (en) 2007-10-18 2013-05-14 Janssen Pharmaceutica Nv Trisubstituted 1,2,4 triazoles

Also Published As

Publication number Publication date
NZ576570A (en) 2010-11-26
ZA200902585B (en) 2010-09-29
EP2508524A3 (en) 2012-10-24
TWI460176B (zh) 2014-11-11
CR10748A (es) 2009-05-20
UA97257C2 (en) 2012-01-25
RU2454415C9 (ru) 2013-02-27
CL2008001017A1 (es) 2009-04-24
US7777047B2 (en) 2010-08-17
TW200825071A (en) 2008-06-16
AU2007310064B2 (en) 2013-03-28
ME00681B (me) 2011-12-20
IL198154A (en) 2014-08-31
IL198154A0 (en) 2009-12-24
US7652133B2 (en) 2010-01-26
RU2009118602A (ru) 2010-11-27
CN101573357B (zh) 2013-01-23
US20100144702A1 (en) 2010-06-10
RU2454415C2 (ru) 2012-06-27
ECSP099330A (es) 2009-06-30
BRPI0717722A2 (pt) 2013-10-29
JP2010506825A (ja) 2010-03-04
US8410087B2 (en) 2013-04-02
EP2074119A1 (en) 2009-07-01
MA30890B1 (fr) 2009-11-02
AU2007310064A2 (en) 2009-06-04
MY158052A (en) 2016-08-30
MEP11809A (en) 2011-12-20
EP2508524A2 (en) 2012-10-10
AU2007310064A1 (en) 2008-05-02
US20100137610A1 (en) 2010-06-03
CN101573357A (zh) 2009-11-04
KR20090068292A (ko) 2009-06-25
WO2008050821A1 (en) 2008-05-02
CA2666973C (en) 2015-03-31
NO20091948L (no) 2009-07-13
US20090286975A1 (en) 2009-11-19
JP5260507B2 (ja) 2013-08-14
GEP20115241B (en) 2011-06-10
CA2666973A1 (en) 2008-05-02
US20080096877A1 (en) 2008-04-24
TN2009000129A1 (en) 2010-10-18
KR101444486B1 (ko) 2014-09-24
MX2009003972A (es) 2009-04-27
US7718798B2 (en) 2010-05-18

Similar Documents

Publication Publication Date Title
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20141375A1 (es) Activadores de glucoquinasa
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20090641A1 (es) Amidas heterociclicas
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20081510A1 (es) Derivados de dihidropiridina como inhibidores de la proteina quinasa
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20091527A1 (es) Derivados de piridazinona
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20090297A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20110063A1 (es) DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20120304A1 (es) Derivados de 1,3-tiazolidina-2,4-diona con actividad sobre quinasas pim-1 y/o pim-2 y/o pim-3
PE20081229A1 (es) Antagonistas de receptor de orexina de diazepam sustituido
PE20110404A1 (es) Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de la orexina
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20091243A1 (es) Compuesto heterociclico fusionado

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed